As Global Race Heats Up for RAS Drugs, Japan Players Joining Fray with New Modalities

As the global race continues for the development of drugs directed at the RAS protein, Japanese pharma majors Astellas Pharma and Chugai Pharmaceutical are entering the fray with new modalities to tackle what was long thought to be an “undruggable”...read more